ESMO 2020 Presentation of Single-agent Anti-PD-1 Balstilimab or in Combination with Anti-CTLA-4 Zalifrelimab for Recurrent/Metastatic (R/M) Cervical Cancer (CC) September 18, 2020 at 9:00 AM CEST View Presentation